Svendsen 1987.

Methods	RCT: cross‐over design. Blinding: double.
Participants	ICS/SCG:38 at entry, 38 at completion (100% completed). Mean age: 29.4 Age range: not reported Gender: 50% male Setting: Copenhagen, Denmark; patients were referred from other hospitals or general practitioners to the outpatient department of allergy. Asthma severity: not reported Inclusion: 1) FEV1 >65 %pred; 2) PC20 <2.0 mg/ml; 3) skin prick test and/or RAST positive to 1 or more common allergens; 4) need for additional antiasthmatic medication besides bronchodilators and/or theophyllines. Exclusion: 1) inhaled steroids or SCG within 4 weeks; 2) oral steroids within 3 mos; 3) seasonal allergies; 4) major medical disease.
Interventions	After a 2 wk run‐in on B2‐agonist and/or theophyllines, patients were randomized to 8 weeks on SCG + placebo BDP or BDP + placebo SCG. After crossover, patients received opposite treatment for final 8 weeks. Duration: 8 weeks. Dose: 200 mcg (ICS); 2mg (SCG) Daily dose: 400 mcg (ICS) Low dose; 8 mg (SCG). Doses/day: 2 (ICS); 4 (SCG). Cumulative dose: 22400 mg (ICS); 448 mg (SCG). Delivery device: MDI
Outcomes	FEV1, PEF, FVC, PC20, reduced activity, sleep disturbance, wheezing, salbutamol use, cough.
Notes	Jadad Quality Score: 4. Possible bias:none
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear

* imputed SD; †change score; 1)Additional 16(ICS) and 23(SCG) drop out from the study